• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

Feb. 23, 2017

View Archived Issues

Keep on Truxima: Celltrion wins EU nod for biosimilar, other submissions nearing

Celltrion Healthcare Inc. planted the oncology flag in biosimilars with the European Commission's approval of Truxima, a biosimilar to Rituxan (rituximab, Roche Holding AG/Biogen Inc.), and the compound will provide estimated health care savings across the 28 countries of the EU of about €570 million (US$602 million) over a three-year period. Read More

Retail investors cash in on Neovacs $69M lupus pact in China

DUBLIN – Shares in Neovacs SA surged by as much as 35 percent Tuesday on news of an option agreement in China worth up to €65 million (US$68.5 million) in up-front and milestone payments for its therapeutic vaccine, IFNα Kinoid, which is currently undergoing a phase IIb trial in lupus. The deal, with Biosense Global LLC, covers Macao, Hong Kong, Taiwan and Singapore, as well as China. Read More

Potential drug target found for Chikungunya virus arthritis

A specific immune system proteinase, granzyme A, was shown to promote arthritic inflammation in mice infected with chikungunya virus (CHIKV), in an Australian study reported in the Feb. 16, 2017, edition of PLOS Pathogens. Read More

Takeda lands Japan rights for cabozantinib in Exelixis agreement

TOKYO – Exelixis Inc. and Takeda Pharmaceutical Co. Ltd. reached an exclusive licensing agreement for the commercialization and further clinical development in Japan of oncology drug cabozantinib. The deal grants Takeda exclusive commercial and further clinical development rights in Japan for cabozantinib. Read More

Financings

Adgero Biopharmaceuticals Holdings Inc., of Princeton, N.J., said it received a $2 million investment from Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd., a publicly traded biopharma firm in Shanghai. Read More

Earnings

United Therapeutics Corp., of Silver Spring, Md., chalked up a "disappointing" fourth quarter in the view of J.P. Morgan analyst Jessica Fye. Revenues of $409 million came in "slightly behind" consensus of $418 million, she noted in a report. Read More

Other news to note

Auris Medical Holding AG, of Zug, Switzerland, said it extended its collaboration with King's College London, which is focused on the discovery of small-molecule compounds for a second-generation tinnitus treatment. It allows for further development with the aim of selecting a lead compound for the AM-102 tinnitus program by the end of this year. Read More

In the clinic

Topivert Pharma Ltd., of London, said it dosed the first patients in a phase I/IIa proof-of-concept study in the U.S. testing TOP1630 ophthalmic solution for the treatment of dry eye syndrome. The study is expected to report in the second half of this year. TOP1630 is a narrow spectrum kinase inhibitor, or NSKI, which has demonstrated efficacy in in vitro and in vivo inflammatory models. Read More

Regulatory front

Leaders of congressional committees dealing with health issues crossed party lines and chambers to urge other U.S. lawmakers to recognize the importance and safety of FDA-approved vaccines. A "dear colleague" letter – signed by Sens. Lamar Alexander (R-Tenn.) and Patty Murray (D-Wash.) and Reps. Greg Walden (R-Ore.), Frank Pallone (D-N.J.), Michael Burgess (R-Texas) and Gene Green (D-Texas) – highlighted the life-saving history of vaccines and recent outbreaks of vaccine-preventable diseases. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 10, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 10, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 10, 2025
  • Red blood cells in an artery with cholesterol

    In two phase IIIs, Merck’s PCSK9 inhibitor cuts cholesterol

    BioWorld
    In two phase III studies, Merck & Co. Inc.’s oral, once monthly proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor produced statistically significant...
  • Cancer cell in the cross-hairs

    Pan-cancer proteome atlas reveals new biomarkers and targets

    BioWorld Science
    An international group of scientists has completed the first draft of The Pan-Cancer Proteome Atlas (TPCPA). The project is based on mass spectrometry of 22...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe